---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-296205"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2021-10-12T23:59:59+00:00"
generated_at: "2026-06-28T21:30:03.073138+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Reneo Pharma appoints Ashley F. Hall as Chief Development Officer

## Summary
- Hall previously CDO at Esperion; oversaw regulatory for NEXLETOL, NEXLIZET, and REPATHA.
- Base salary $420,000, bonus up to 40%, housing reimbursement up to $5,000/month.
- Relocation assistance of $150,000 if relocated within 18 months.
- Equity inducement: option for 180,000 shares (4-yr vest) and RSU for 30,000 shares (vests on first NDA/MAA).
- Severance: 9 months base/COBRA; on change in control 12 months plus full equity acceleration.

## SEC filing metadata
- accession: 0001193125-21-296205
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2021-10-12T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000119312521296205/0001193125-21-296205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000119312521296205/d239269d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-296205
- JSON: https://secwatch.observer/filing/0001193125-21-296205.json
- Plain text: https://secwatch.observer/filing/0001193125-21-296205.txt

## Key facts
- Executive change
  Ashley F. Hall was appointed as Chief Development Officer at OnKure Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Development Officer
  source text: On October 11, 2021, Reneo Pharmaceuticals, Inc. (the “Company”) announced the appointment of Ashley F. Hall, J.D., as the Chief Development Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312521296205/0001193125-21-296205-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.